Direct Spraying of MINCLEA on the Duodenal Papilla for Preventing Post-ERCP Pancreatitis
Not Applicable
Recruiting
- Conditions
- post-ERCP pancreatitis
- Registration Number
- JPRN-UMIN000013086
- Lead Sponsor
- Department of Gastroenterology, Sapporo City General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with hypersensitivity to MINCLEA. 2) Patients with a history of EST and EPBD. 3) Patients with receiving endoscopic therapy of ENBD, ENPD, biliary stent or pancreatic stent. 4) Patients with acute pancreatitis. 5) Patients with chronic pancreatitis. 6) Patients with divism or pancreaticobiliary maljunction 7) Patients who are judged inappropriate by chief (responsive) medical examiner.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence rate of post-ERCP pancreatitis
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MINCLEA utilize to inhibit post-ERCP pancreatitis via Mincle receptor activation?
How does direct MINCLEA application compare to rectal NSAIDs in preventing post-ERCP pancreatitis efficacy?
Which inflammatory biomarkers correlate with MINCLEA response in post-ERCP pancreatitis prevention trials?
What are the safety profiles of MINCLEA versus pancreatic stent placement for post-ERCP pancreatitis prophylaxis?
Are there alternative C-type lectin receptor agonists being studied for post-ERCP pancreatitis prevention alongside MINCLEA?